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Abstract: Thioredoxin-interacting protein (TXNIP) is involved in multiple disease-associated func-
tions related to oxidative stress, especially by inhibiting the anti-oxidant- and thiol-reducing activity
of thioredoxin (TXN). Shiga-Y5 (SY5), a fluorine-19 magnetic resonance probe for detecting amyloid-β
deposition in the brain, previously showed therapeutic effects in a mouse model of Alzheimer’s
disease; however, the mechanism of action of SY5 remains unclear. SY5 passes the blood–brain barrier
and then undergoes hydrolysis to produce a derivative, Shiga-Y6 (SY6), which is a TXNIP-negative
regulator. Therefore, this study investigates the therapeutic role of SY5 as the prodrug of SY6 in
the thioredoxin system in the brain of a mouse model of Alzheimer’s disease. The intraperitoneal
injection of SY5 significantly inhibited TXNIP mRNA (p = 0.0072) and protein expression (p = 0.0143)
induced in the brain of APP/PS1 mice. In contrast, the levels of TXN mRNA (p = 0.0285) and protein
(p = 0.0039) in the brain of APP/PS1 mice were increased after the injection of SY5. The ratio of
TXN to TXNIP, which was decreased (p = 0.0131) in the brain of APP/PS1 mice, was significantly
increased (p = 0.0072) after the injection of SY5. These results suggest that SY5 acts as a prodrug of
SY6 in targeting the thioredoxin system and could be a potential therapeutic compound in oxidative
stress-related diseases in the brain.
Keywords: curcumin; oxidative stress; thioredoxin; TXNIP; Alzheimer’s disease
1. Introduction
Thioredoxin-interacting protein (TXNIP) plays an important role in the redox system,
but it is implicated differently in many diseases, including cancers, diabetes, and neurode-
generative disorders [1]. Additionally, TXNIP is an endogenous intracellular inhibitor of
thioredoxin (TXN), an anti-oxidant protein in the thiol-reductase redox system [2]. TXNIP
expression is highly triggered by glucose and is increased in the beta-cells (β-cells) of
patients with diabetes [3], inhibiting TXN function and inducing increased levels of freely
diffusible molecular hydrogen peroxide; it contributes to oxidative stress and eventually
β-cell death [4]. Studies showed that TXNIP inhibition prevented β-cell apoptosis and
protected against diabetes [5,6]. In contrast, TXNIP was underexpressed in most cancers,
leading to high cell proliferation [7]. Mechanisms of TXNIP downregulation include the
interaction of microRNAs with the 3′ untranslated region (UTR), the binding of transcrip-
tion factors, and epigenetic changes in the promoter region of TXNIP [8]. Thus, inducing
TXNIP expression could remarkably block the cell cycle and suppress tumor cells [9,10].
TXNIP’s involvement in Alzheimer’s disease (AD) is mostly associated with inflam-
mation and accompanied by other processes, such as amyloid β (Aβ) deposition and
neurofibrillary tangles [11,12]. Recent studies have demonstrated that TXNIP protein
Molecules 2021, 26, 5342. https://doi.org/10.3390/molecules26175342 https://www.mdpi.com/journal/molecules
Molecules 2021, 26, 5342 2 of 9
expression was upregulated and colocalized near Aβ plaques and phosphorylated tau
(p-tau) [13]. In contrast, in a separate study, TXN protein levels were downregulated in
the brains of AD mice [14,15]. A consistent finding showed that TXNIP protein expression
increased significantly in the hippocampus and frontal cortex of Aβ precursor protein
and presenilin 1 (APP/PS1) transgenic mice and primary cultured mouse cerebral cortex
neurons HT22 mouse hippocampal cells treated with Aβ peptide [16]. TXNIP remained an
exclusive marker in microglia, neurons, astrocytes, and endothelial cells [17–19]. TXNIP
has been proposed as an essential mediator of nucleotide-binding oligomerization domain-,
leucine-rich repeat- and pyrin domain-containing 3 (NLRP3) inflammasome activation and
the eventual formation of activated caspase 1 [13]. Preventing the interaction of TXNIP
with NLRP3 demonstrated positive effects by reversing or restraining AD pathology [20,21].
Considering the involvement of TXNIP in the pathology of the disease, targeting these
proteins might be the possible therapeutic target for intervention.
Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) (Figure 1a),
a polyphenol also called diferuloylmethane, is the low molecular weight yellow–orange
pigment derived from a rhizomatous herbaceous perennial plant (Curcuma longa) of
the ginger family known as turmeric [22]. We previously reported a novel curcumin
derivative, 1,7-Bis(4′-hydroxy-3′-trifluoromethoxyphenyl)-4-methoxycarbonylethyl-1,6-
heptadiene-3,5-dione, named Shiga-Y5 (SY5) (Figure 1b), which was synthesized in our
laboratory as a fluorine-19 magnetic resonance (19F MR) probe to detect amyloid deposition
in the Tg2576 mouse [23]. SY5 contains six fluorine atoms and bears a substitution at the
C-4 position, influencing the ratio of keto to enol tautomer and its effects on amyloid β
(Aβ) aggregation [24]. Our previous study demonstrated that only SY5 is effective against
Aβ toxicity; it improved cognitive impairment, inhibited amyloid deposition and reduced
glial activation in APP/PS1 mice [25].
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acid groups at the C-4 position as obtained by the hydrolysis of Shiga-Y5.
Several studies have demonstrated the therapeutic effect of curcumin, as seen by the
increased TXN protein expression [26] and decreased TXNIP protein expression [27] in cells
subjected to oxidative stress. A curcumin derivative with the carbonic acid group named
Shiga-Y6 (SY6) (Figure 1c) showed negative regulation on TXNIP expression in culture cells
exposed to high glucose and endoplasmic reticulum stress inducer [28]. Our preliminary
study showed that SY5 passes the blood–brain barrier (BBB), and the methyl ester group
undergoes hydrolysis in the brain to produce SY6; however, the mechanism remains
unclear. This finding suggests that acting as a prodrug of SY6 is a possible mechanism
of action of SY5 to inhibit TXNIP, leading to the therapeutic effect in the AD model mice.
Here, we investigated the role of SY5 as the prodrug of SY6 in the thioredoxin system,
which might be a possible target for intervention in AD.
2. Results
2.1. Gene Expression of TXN and TXNIP
Our previous study using SY5 indicated that the dose of 200 mg/kg was tolerated and
can cross the BBB after intravenous injection in APP/PS1 mice [23]. In this study, the same
dose of SY5 (200 mg/kg) was administered by intraperitoneal injection (i.p). After 2 h,
the mice were sacrificed, the brain was quickly removed, and the cerebral cortex and liver
were isolated and cut in half for the gene and protein expression analysis. In the brain’s
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cerebral cortex, the TXN mRNA level was unchanged in APP/PS1 mice compared with
WT mice. However, with SY5 treatment, the TXN mRNA level was significantly increased
(p = 0.0285). In contrast, TXNIP mRNA level was significantly increased (p = 0.0224) in
APP/PS1 mice compared with WT mice, and with SY5 treatment, TXNIP mRNA level
was significantly decreased (p = 0.0072) compared to without treatment in APP/PS1 mice
(Figure 2a). There were no significant differences in the liver in TXN or TXNIP mRNA
levels between APP/PS1 and WT mice and between APP/PS1 mice with or without SY5
treatment (Figure 2b).
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2.2. Protein Expression of TXN and TXNIP
We further investigated the effect of SY5 on the protein level of TXN and TXNIP in
APP/PS1 mice. Protein extracts from the cerebral cortex and the liver were electrophoresed
on SDS gel, and the protein bands of TXN and TXNIP were detected at the estimated size of
12 and 52 kDa, respectively (Figure 3a,b). Full-length blots are presented in Supplementary
Figures S1 and S2. In the brain’s cerebral cortex, the TXN protein expression level showed a
decreasing trend but was not statistically significant in APP/PS1 mice compared with WT
mice. In contrast, there was a significant increase (p = 0.0039) in the TXN protein expression
lev l with SY5 tre tm nt than without treatment in APP/PS1 mice (Figure 3c). Furthermore,
the TXNIP protein expression level demonstrated a signifi t i rease (p = 0.0126) in
APP/PS1 mice compared with WT mice; the increased level of TXNIP was significantly
reversed (p = 0.0143) with SY5 treatment compared with without treatment in APP/PS1
mice (Figure 3d). Additionally, the ratio of TXN/TXNIP significantly decreased (p = 0.0131)
in APP/PS1 compared with WT mice; however, the decreased ratio of TXN/TXNIP was
more significantly reversed (p = 0.0072) with SY5 treatment than without treatment in
APP/PS1 mice (Figure 3e). Meanwhile, in the liver, consistent with the mRNA level, there
were no significant differences in TXN or TXNIP protein expression level and the ratio of
TXN/T IP between APP/PS1 and WT mice and between APP/PS1 m ce with or without
SY5 treatment (Figure 3f–h).
Molecules 2021, 26, 5342 4 of 9




Figure 3. The TXN or TXNIP protein expression level in the APP/PS1 mice. Representative images 
of Western blotting for TXN, TXNIP, and β-actin in (a) the brain and (b) liver. Densitometric anal-
ysis of TXN or TXNIP and calculation of the ratio of TXN/TXNIP in the cerebral cortex of the brain 
(c–e) and the liver (f–h). Data are presented as mean ± SEM (n = 6). Significance: ** p < 0.01, * p < 
0.05. Full-length blots are presented in Supplementary Figures S1 and S2. 
3. Discussion 
In this study, we investigated the role of SY5 in regulating TXN and TXNIP in 
APP/PS1 mice. It had been initially hypothesized that targeting TXNIP by lowering its 
levels would prevent the inhibitory binding to TXN, which might reduce oxidative stress. 
Our results show that the TXNIP protein expression level was initially upregulated in the 
brain of APP/PS1 mice; however, with SY5 treatment, it was downregulated and accom-
panied by the upregulation of TXN at the transcriptional and translational levels. In con-
trast, we found no changes in TXN or TXNIP levels in the liver, suggesting that SY5 acts 
as a signaling molecule targeting the thioredoxin system in the brain of APP/PS1 mice. 
Consistent with the previous study, the protein expression of TXNIP increased sig-
nificantly without changes in TXN in the brain of APP/PS1 mice at 9 and 12 months of age 
when Aβ deposits had developed compared with wild-type mice [16]. Several studies 
ig re 3. r I r tei ex ression level in the PP/
of estern blotting for TXN, TXNIP, and β-actin in (a) the brain and (b) liver. Densitometric an lysis
of TXN or TXNIP and calculation of the ratio of TXN/TXNIP in the cerebral cortex of the brain (c–e)
and the liver (f–h). Data are presented as mean ± SEM (n = 6). Significance: ** p < 0.01, * p < 0.05.
Full-length blots are presented in Supplementary Figures S1 and S2.
3. Discussion
In this study, we investigated the role of SY5 in regulating TXN and TXNIP in APP/PS1
mice. It had been initially hypothesized that targeting TXNIP by lowering its levels would
prevent the inhibitory binding to TXN, which might reduce oxidative stress. Our results
show that the TXNIP protein expression level was initially upregulated in the brain of
APP/PS1 mice; however, ith SY5 treatment, it was do nregulated and accompanied
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of age when Aβ deposits had developed compared with wild-type mice [16]. Several
studies have demonstrated that TXNIP is required to activate NLRP3 inflammasome, a
prevalent proposed mechanism in mediating inflammation in AD [13,29,30]. Activated
NLRP3 recruited the adapter protein apoptosis-associated specklike (ASC) and pro-caspase
1, leading to caspase 1 production and subsequent interleukin-1β (IL-1β) maturation and
release, activating signaling pathways and resulting in neuroinflammation and neuronal
death [13,31,32]. Inhibiting TXNIP was elevated during disease development or in the
presence of cellular stress factors, which showed several benefits, particularly in reversing
the pathological outcomes. For example, the inhibitory effects of curcumin on TXNIP may
have caused failed activation of the NLRP3 inflammasome, subsequently suppressing the
upregulation of proinflammatory cytokines and improving paraquat-induced oxidative
stress in lung fibroblast cells [27]. Similar effects of curcumin were also demonstrated
whereby TXNIP/NLRP3 inflammasome activation was inhibited, suppressing endoplas-
mic reticulum stress and protecting neuronal cell survival in mice hippocampus-induced
glutamate neurotoxicity [33].
Previously, we have synthesized and reported at least two 19F MR probes contain-
ing different novel contrast agents to detect amyloid deposits in the brain of transgenic
mouse models of AD [34]. These include curcumin (Shiga-Y) [23] and styrylbenzoxazole
derivatives (Shiga-X) [35], which possess fluorine substituents to detect 19F MR signals.
MR sensitivity of 19F is high compared with various nuclei other than 1H (1H, 100%; 19F,
83%; 31P, 6.6%; 13C, 1.6%). No detectable fluorine atoms exist in biological tissues (fluorine
in bones and teeth is inappropriate for 19F MRI relaxation time), which could result in
low endogenous background noise. Furthermore, the 19F atom is a nonradioactive isotope
comprising 100% of naturally abundant fluorine. Thus, 19F MRI is a highly sensitive,
readily available, low-background, and cost-effective approach once a suitable high-quality
probe has been developed. Among more than 40 19F MR probes containing curcumin
derivatives synthesized in our laboratory, the one typically used for amyloid imaging in
the mouse brain using MRI was SY5 [36]. SY5 contained six 19F atoms in two CF3 groups,
which display a single sharp 19F nuclear magnetic resonance (NMR) signal in solution
and could bind to senile plaques in human brain sections. However, when these chem-
icals were intravenously injected into the tail veins of the APP transgenic mouse model
(Tg2576), only SY5 passed through the BBB and bound to Aβ plaques (Supplementary
Figure S3). In contrast, SY6 did not bind to Aβ plaques due to poor permeability into the
brain (Supplementary Figure S3) [36].
Previous studies in our laboratory showed that SY6 demonstrated significantly greater
activity in inhibiting TXNIP expression and enhancing TXN expression in cellular models
of diabetes, endoplasmic reticulum stress, and inflammation while possessing the anti-
inflammatory properties of native curcumin [28]. However, SY6 could not cross the BBB,
limiting its further investigation in an animal model. Our preliminary study showed
that SY5 could be converted to SY6 when entering the brain; however, the mechanism
remains unclear. Thus, we speculate that the inhibitory effect of SY5 on TXNIP and TXN
upregulation in the brain was possibly from the action exerted by SY6. However, the action
exerted by SY5 on TXNIP may be independent of conversion to SY6. Further study is
needed to discover more about the mechanism of action of SY5.
We also demonstrated that in the microenvironment surrounding Aβ plaques, SY5,
which bears a substitution at the C-4 position, likely exists in equilibrium between the free
(keto) and bound (enol) forms to influence their effects on amyloid β (Aβ) aggregation.
Additionally, only the enol form of this compound can bind to Aβ aggregates/fibrils [24]
and Aβ oligomers [37] but not to Aβ monomers. Furthermore, 19F NMR signals displayed
by SY5 showed dose-dependently as it was hardly detected at a dose of 50 mg/kg but easily
detected at a dose of 100 mg/kg and tolerable up to a dose of 200 mg/kg [23]. Histological
analysis of SY5 following intravenous injection in APP/PS1 mice showed strong fluorescent
signals in the cortex and hippocampus, with most of this signal colocalized with Aβ
immunoreactivity [23]. Furthermore, we demonstrated that only SY5 inhibited behavioral
Molecules 2021, 26, 5342 6 of 9
deficit, as seen in the water maze test, a significant reduction in latencies for the platform
at days 5 and 6, compared with day 1 in APP/PS1 mice besides comparable time spent
in the targeted quadrant to that in WT mice [25]. Our previous studies show that Aβ in
the form of fibrils and oligomers are targeted by SY5 and improved cognitive function in
APP/PS1 mice. Possibly, there will be more targeted proteins to explain the mechanisms of
action and therapeutic effects of this compound.
There were some limitations in this study, including no investigation regarding
changes in TXNIP levels in SY5-injected wild-type mice, the effect of SY5 on cognitive
function and Aβ accumulation in the brain, and the detailed mechanism of how SY5 acts
as a TXNIP modulator in the brain. Further study is needed to clarify these points.
Summarily, these data indicate directions for future studies for characterizing the
properties of curcumin derivatives. We have produced many chemically modified cur-
cumin derivatives that can be tested in these simple assays to modulate TXNIP and TXN
expression.
4. Materials and Methods
4.1. Animals
All animal experiments were conducted according to the National Institutes of Health
Guide for the Care and Use of Laboratory Animals and approved by the Institutional
Ethics Committee of Shiga University of Medical Science (2021-6-10). APP/PS1 mice with
a C57BL/6 background (Jackson Laboratory, Bar Harbor, ME, USA), expressing a chimeric
mouse/human amyloid precursor protein with the K594N and M595L mutations linked to
Swedish familial AD (Mo/HuAPP695swe) and human PS1, carrying the exon 9 deletion
associated with familial AD [38] were used in this study. The mice were housed in standard
laboratory cages at 23 ◦C with free access to water and food in an SPF animal facility and
maintained with a 12 h light/dark cycle with lights on from 8:00 a.m. to 8:00 p.m.
4.2. Treatment Groups
Shiga-Y5 was dissolved at a concentration of 10 mg/mL in saline containing 10%
Cremophor EL. The WT mice (n = 6) aged 10–12 months received an intraperitoneal
injection (i.p.) of normal saline containing 10% Cremophor EL. The APP/PS1 mice aged
10–12 months were divided into two groups, with six mice in each group and received i.p.
normal saline (Tg) and Shiga-Y5 at 200 mg/kg (Tg-SY5). After 2 h, the mice were sacrificed
under deep anesthesia using sodium pentobarbital (200 mg/kg, i.p.); the brain was quickly
removed from each mouse. The cerebral cortex tissues from the right hemisphere and the
liver were isolated and snap-frozen in liquid nitrogen and stored at −80 ◦C until further
use for gene and protein expression analysis.
4.3. Preparation of Protein Extracts from Brain and Liver Tissue
Brain and liver tissue were homogenized in 10 volumes of Tris-buffered saline (TBS;
25 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EGTA, protease inhibitor cocktail (Roche
Diagnostic, Mannheim, Germany) and phosphatase inhibitor cocktail (Roche Diagnostic))
added to Triton X-100 (1% final concentration), kept on ice for 60 min and centrifuged at
10,000× g, 4 ◦C for 15 min. The supernatant was collected, and the protein concentration
was determined using a Protein Assay Bicinchoninate kit (Nacalai Tesque, Kyoto, Japan).
4.4. Western Blotting
Proteins (10 µg) in 4x sample buffer and 10x reducing buffer (Life Technologies,
Waltham, MA, USA) were denatured at 95 ◦C for 10 min, applied to the lanes of precast
15% polyacrylamide gels (Wako Pure Chemicals, Osaka, Japan), electrophoresed, and
transferred to polyvinylidene difluoride membranes (Immobilon-P; Merck Millipore, MA,
USA). The membranes were blocked with 5% skim milk in Tris-buffered saline containing
1% Tween 20 (TBST) at room temperature for 1 h, followed by overnight incubation at 4 ◦C
with the primary antibodies including rabbit monoclonal antibodies against thioredoxin
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(ab273877; 1:1000; Abcam, Cambridge, UK), TXNIP (ab188865; 1:2000, Abcam) and mouse
monoclonal antibody against β-actin (1:5000; Santa Cruz Biotechnology, Dallas, TX, USA).
The membranes were further incubated with horseradish peroxidase-conjugated goat
polyclonal antibody against rabbit immunoglobulin (Ig)G (1:10,000; Jackson ImmunoRe-
search, West Grove, PA, USA) and mouse IgG (1:10,000; Jackson ImmunoResearch) for
1 h at room temperature. Immunoreactivity proteins were visualized with a chemilumi-
nescence substrate (SuperSignal West Pico PLUS Chemiluminescence Substrate; Thermo
Fisher Scientific, Waltham, MA, USA) using Western blotting imager (Fusion Solo S, Vilber,
Nantes, France). The band density was analyzed using image processing software (ImageJ;
National Institutes of Health, Bathesda, MD, USA).
4.5. RNA Isolation and Quantitative Polymerase Chain Reaction (qPCR)
Total RNA was extracted from the cerebral cortex and the liver using RNeasy Lipid
Tissue Mini and RNeasy Plus Universal Mini Kit (Qiagen, Hilden, Germany), respec-
tively, following the manufacturer’s protocol. RNA samples were reverse transcribed
into cDNA using ReverTra Ace qPCR RT Master Mix with gDNA Remover kit (Toyobo,
Osaka, Japan) in accordance with the manufacturer’s protocol. qPCR was conducted in
duplicate 10 µL reactions containing 2-µL cDNA, 5-µL TaqMan Fast Advanced Master Mix
(Applied Biosystem, Waltham, MA, USA), 0.5-µL TaqMan Gene Expression assay (TXN,
Mm00726847_s1; TXNIP, Mm00452393_m1; ACTB, Mm01205647_g1) (Applied Biosystem)
and 3.5 µL of RNase free water on a LightCycler 480 instrument (Roche Diagnostic) using
the following cycling parameters: Uracil N-glycosylase incubation at 50 ◦C for 2 min,
polymerase activation at 95 ◦C for 2 min, followed by 40 cycles of denaturation at 95◦C for
1 s, annealing/extension at 60 ◦C for 20 s.
4.6. Statistical Analysis
Statistical analyses were performed using GraphPad PRISM v.8 software (GraphPad
Software, San Diego, CA, USA). Data are presented as the mean ± standard error of
the mean (SEM). Statistical comparisons between groups were performed using one-way
ANOVA followed by Sidak post hoc test. The statistical significance of all tests was set at
p < 0.05.
5. Patents
Shiga University of Medical Science obtained a Japanese patent (JP2012-260046) on
SY5 and SY6, with D.Y., H.T., and I.T. named as the inventors, and has submitted another
Japanese patent application (JP2020-141272) on SY6, with D.Y., H.T., and I.T. named as the
inventors.
Supplementary Materials: The following are available, Figure S1: Full-length blots in Figure 2a,
Figure S2: Full-length blots in Figure 2b, Figure S3: 19F MRI using Shiga-Y5 and Shiga-Y6.
Author Contributions: Conceptualization, D.Y. and I.T.; formal analysis, A.P.A.; investigation, A.P.A.
and D.Y.; resources, H.T. and I.T.; writing—original draft preparation, A.P.A.; writing—review and
editing, Z.H.A.B., H.T., D.Y., I.T.; visualization, A.P.A.; supervision, D.Y. and I.T.; funding acquisition,
H.T. and I.T. All authors have read and agreed to the published version of the manuscript.
Funding: This research was funded by JSPS KAKENHI, grant numbers JP19K12780 (H.T.).
Institutional Review Board Statement: The study was conducted according to the National Insti-
tutes of Health Guide for the Care and Use of Laboratory Animals and approved by the Institutional
Ethics Committee of Shiga University of Medical Science (10 June 2021).
Informed Consent Statement: Not applicable.
Data Availability Statement: The data presented in this study are available on request from the
corresponding author.
Acknowledgments: The authors would like to thank Yasuko Hata and the staff of the Central
Research Laboratory, Shiga University of Medical Science, for their technical assistance.
Molecules 2021, 26, 5342 8 of 9
Conflicts of Interest: The authors declare no conflict of interest.
Sample Availability: Sample of the compounds are available from the authors.
References
1. Hu, J.; Yu, Y. The Function of Thioredoxin-Binding Protein-2 (TBP-2) in Different Diseases. Oxid. Med. Cell. Longev. 2018, 2018,
4582130. [CrossRef]
2. Alhawiti, N.M.; Al Mahri, S.; Aziz, M.A.; Malik, S.S.; Mohammad, S. TXNIP in Metabolic Regulation: Physiological Role and
Therapeutic Outlook. Curr. Drug Targets 2017, 18, 1095–1103. [CrossRef] [PubMed]
3. Shalev, A. Minireview: Thioredoxin-interacting protein: Regulation and function in the pancreatic β-cell. Mol. Endocrinol. 2014,
28, 1211–1220. [CrossRef] [PubMed]
4. Thielen, L.; Shalev, A. Diabetes pathogenic mechanisms and potential new therapies based upon a novel target called TXNIP.
Curr. Opin. Endocrinol. Diabetes Obes. 2018, 25, 75–80. [CrossRef] [PubMed]
5. Wondafrash, D.Z.; Nire’a, A.T.; Tafere, G.G.; Desta, D.M.; Berhe, D.A.; Zewdie, K.A. Thioredoxin-Interacting Protein as a Novel
Potential Therapeutic Target in Diabetes Mellitus and Its Underlying Complications. Diabetes Metab. Syndr. Obes. 2020, 13, 43–51.
[CrossRef]
6. Panse, M.; Kluth, O.; Lorza-Gil, E.; Kaiser, G.; Mühlbauer, E.; Schürmann, A.; Häring, H.-U.; Ullrich, S.; Gerst, F. Palmitate and
insulin counteract glucose-induced thioredoxin interacting protein (TXNIP) expression in insulin secreting cells via distinct
mechanisms. PLoS ONE 2018, 13, e0198016. [CrossRef]
7. Jia, J.-J.; Geng, W.-S.; Wang, Z.-Q.; Chen, L.; Zeng, X.-S. The role of thioredoxin system in cancer: Strategy for cancer therapy.
Cancer Chemother. Pharmacol. 2019, 84, 453–470. [CrossRef]
8. Chen, Y.; Ning, J.; Cao, W.; Wang, S.; Du, T.; Jiang, J.; Feng, X.; Zhang, B. Research Progress of TXNIP as a Tumor Suppressor Gene
Participating in the Metabolic Reprogramming and Oxidative Stress of Cancer Cells in Various Cancers. Front. Oncol. 2020, 10,
1861. [CrossRef]
9. Xie, M.; Xie, R.; Xie, S.; Wu, Y.; Wang, W.; Li, X.; Xu, Y.; Liu, B.; Zhou, Y.; Wang, T.; et al. Thioredoxin interacting protein (TXNIP)
acts as a tumor suppressor in human prostate cancer. Cell Biol. Int. 2020, 44, 2094–2106. [CrossRef] [PubMed]
10. Morrison, J.A.; Pike, L.A.; Sams, S.B.; Sharma, V.; Zhou, Q.; Severson, J.J.; Tan, A.-C.; Wood, W.M.; Haugen, B.R. Thioredoxin
interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer. Mol. Cancer 2014, 13, 62. [CrossRef]
11. DeTure, M.A.; Dickson, D.W. The neuropathological diagnosis of Alzheimer’s disease. Mol. Neurodegener. 2019, 14, 32. [CrossRef]
12. Bloom, G.S. Amyloid-β and tau: The trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 2014, 71, 505–508.
[CrossRef] [PubMed]
13. Li, L.; Ismael, S.; Nasoohi, S.; Sakata, K.; Liao, F.-F.; McDonald, M.P.; Ishrat, T. Thioredoxin-Interacting Protein (TXNIP) Associated
NLRP3 Inflammasome Activation in Human Alzheimer’s Disease Brain. J. Alzheimer’s Dis. 2019, 68, 255–265. [CrossRef]
14. Akterin, S.; Cowburn, R.F.; Miranda-Vizuete, A.; Jiménez, A.; Bogdanovic, N.; Winblad, B.; Cedazo-Minguez, A. Involvement of
glutaredoxin-1 and thioredoxin-1 in β-amyloid toxicity and Alzheimer’s disease. Cell Death Differ. 2006, 13, 1454–1465. [CrossRef]
[PubMed]
15. Lovell, M.A.; Xie, C.; Gabbita, S.P.; Markesbery, W.R. Decreased thioredoxin and increased thioredoxin reductase levels in
Alzheimer’s disease brain. Free Radic. Biol. Med. 2000, 28, 418–427. [CrossRef]
16. Wang, Y.; Wang, Y.; Bharti, V.; Zhou, H.; Hoi, V.; Tan, H.; Wu, Z.; Nagakannan, P.; Eftekharpour, E.; Wang, J.-F. Upregulation of
Thioredoxin-Interacting Protein in Brain of Amyloid-β Protein Precursor/Presenilin 1 Transgenic Mice and Amyloid-β Treated
Neuronal Cells. J. Alzheimer’s Dis. 2019, 72, 139–150. [CrossRef]
17. Mangialasche, F.; Polidori, M.C.; Monastero, R.; Ercolani, S.; Camarda, C.; Cecchetti, R.; Mecocci, P. Biomarkers of oxidative
and nitrosative damage in Alzheimer’s disease and mild cognitive impairment. Ageing Res. Rev. 2009, 8, 285–305. [CrossRef]
[PubMed]
18. Mariani, E.; Polidori, M.C.; Cherubini, A.; Mecocci, P. Oxidative stress in brain aging, neurodegenerative and vascular diseases:
An overview. J. Chromatogr. B. Anal. Technol. Biomed. Life Sci. 2005, 827, 65–75. [CrossRef]
19. Butterfield, D.A.; Poon, H.F.; St Clair, D.; Keller, J.N.; Pierce, W.M.; Klein, J.B.; Markesbery, W.R. Redox proteomics identification
of oxidatively modified hippocampal proteins in mild cognitive impairment: Insights into the development of Alzheimer’s
disease. Neurobiol. Dis. 2006, 22, 223–232. [CrossRef]
20. Pan, Q.; Guo, K.; Xue, M.; Tu, Q. Estrogen protects neuroblastoma cell from amyloid-β 42 (Aβ42)-induced apoptosis via
TXNIP/TRX axis and AMPK signaling. Neurochem. Int. 2020, 135, 104685. [CrossRef]
21. Wang, C.-Y.; Xu, Y.; Wang, X.; Guo, C.; Wang, T.; Wang, Z.-Y. Dl-3-n-Butylphthalide Inhibits NLRP3 Inflammasome and Mitigates
Alzheimer’s-Like Pathology via Nrf2-TXNIP-TrX Axis. Antioxid. Redox Signal. 2019, 30, 1411–1431. [CrossRef] [PubMed]
22. Priyadarsini, K.I. The chemistry of curcumin: From extraction to therapeutic agent. Molecules 2014, 19, 20091–20112. [CrossRef]
[PubMed]
23. Yanagisawa, D.; Amatsubo, T.; Morikawa, S.; Taguchi, H.; Urushitani, M.; Shirai, N.; Hirao, K.; Shiino, A.; Inubushi, T.; Tooyama,
I. In vivo detection of amyloid β deposition using 19F magnetic resonance imaging with a 19F-containing curcumin derivative in
a mouse model of Alzheimer’s disease. Neuroscience 2011, 184, 120–127. [CrossRef] [PubMed]
Molecules 2021, 26, 5342 9 of 9
24. Yanagisawa, D.; Shirai, N.; Amatsubo, T.; Taguchi, H.; Hirao, K.; Urushitani, M.; Morikawa, S.; Inubushi, T.; Kato, M.; Kato, F.;
et al. Relationship between the tautomeric structures of curcumin derivatives and their Abeta-binding activities in the context of
therapies for Alzheimer’s disease. Biomaterials 2010, 31, 4179–4185. [CrossRef]
25. Yanagisawa, D.; Ibrahim, N.F.; Taguchi, H.; Morikawa, S.; Hirao, K.; Shirai, N.; Sogabe, T.; Tooyama, I. Curcumin derivative with
the substitution at C-4 position, but not curcumin, is effective against amyloid pathology in APP/PS1 mice. Neurobiol. Aging 2015,
36, 201–210. [CrossRef] [PubMed]
26. Wu, J.-X.; Zhang, L.-Y.; Chen, Y.-L.; Yu, S.-S.; Zhao, Y.; Zhao, J. Curcumin pretreatment and post-treatment both improve the
antioxidative ability of neurons with oxygen-glucose deprivation. Neural Regen. Res. 2015, 10, 481–489. [CrossRef]
27. Ren, Y.; Yang, Z.; Sun, Z.; Zhang, W.; Chen, X.; Nie, S. Curcumin relieves paraquat-induced lung injury through inhibiting the
thioredoxin interacting protein/NLR pyrin domain containing 3-mediated inflammatory pathway. Mol. Med. Rep. 2019, 20,
5032–5040. [CrossRef]
28. Buyandelger, U.; Walker, D.G.; Taguchi, H.; Yanagisawa, D.; Tooyama, I. Novel fluorinated derivative of curcumin negatively
regulates thioredoxin-interacting protein expression in retinal pigment epithelial and macrophage cells. Biochem. Biophys. Res.
Commun. 2020, 532, 668–674. [CrossRef]
29. Ismael, S.; Wajidunnisa; Sakata, K.; McDonald, M.P.; Liao, F.-F.; Ishrat, T. ER stress associated TXNIP-NLRP3 inflammasome
activation in hippocampus of human Alzheimer’s disease. Neurochem. Int. 2021, 148, 105104. [CrossRef]
30. Qayyum, N.; Haseeb, M.; Kim, M.S.; Choi, S. Role of Thioredoxin-Interacting Protein in Diseases and Its Therapeutic Outlook.
Int. J. Mol. Sci. 2021, 22, 2754. [CrossRef]
31. Heneka, M.T.; Kummer, M.P.; Stutz, A.; Delekate, A.; Schwartz, S.; Vieira-Saecker, A.; Griep, A.; Axt, D.; Remus, A.; Tzeng,
T.-C.; et al. NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature 2013, 493, 674–678.
[CrossRef] [PubMed]
32. Wright, A.L.; Zinn, R.; Hohensinn, B.; Konen, L.M.; Beynon, S.B.; Tan, R.P.; Clark, I.A.; Abdipranoto, A.; Vissel, B. Neuroinflam-
mation and neuronal loss precede Aβ plaque deposition in the hAPP-J20 mouse model of Alzheimer’s disease. PLoS ONE 2013,
8, e59586. [CrossRef] [PubMed]
33. Li, Y.; Li, J.; Li, S.; Li, Y.; Wang, X.; Liu, B.; Fu, Q.; Ma, S. Curcumin attenuates glutamate neurotoxicity in the hippocampus by
suppression of ER stress-associated TXNIP/NLRP3 inflammasome activation in a manner dependent on AMPK. Toxicol. Appl.
Pharmacol. 2015, 286, 53–63. [CrossRef]
34. Tooyama, I.; Yanagisawa, D.; Taguchi, H.; Kato, T.; Hirao, K.; Shirai, N.; Sogabe, T.; Ibrahim, N.F.; Inubushi, T.; Morikawa,
S. Amyloid imaging using fluorine-19 magnetic resonance imaging ((19)F-MRI). Ageing Res. Rev. 2016, 30, 85–94. [CrossRef]
[PubMed]
35. Yanagisawa, D.; Taguchi, H.; Ibrahim, N.F.; Morikawa, S.; Shiino, A.; Inubushi, T.; Hirao, K.; Shirai, N.; Sogabe, T.; Tooyama, I.
Preferred features of a fluorine-19 MRI probe for amyloid detection in the brain. J. Alzheimer’s Dis. 2014, 39, 617–631. [CrossRef]
[PubMed]
36. Taguchi, H.; Yanagisawa, D.; Morikawa, S.; Hirao, K.; Shirai, N.; Tooyama, I. Synthesis and Tautomerism of Curcumin Derivatives
and Related Compounds. Aust. J. Chem. 2015, 68, 224–229. [CrossRef]
37. Yanagisawa, D.; Taguchi, H.; Yamamoto, A.; Shirai, N.; Hirao, K.; Tooyama, I. Curcuminoid binds to amyloid-β1-42 oligomer and
fibril. J. Alzheimer’s Dis. 2011, 24 (Suppl. 2), 33–42. [CrossRef]
38. Jankowsky, J.L.; Fadale, D.J.; Anderson, J.; Xu, G.M.; Gonzales, V.; Jenkins, N.A.; Copeland, N.G.; Lee, M.K.; Younkin, L.H.;
Wagner, S.L.; et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: Evidence for
augmentation of a 42-specific gamma secretase. Hum. Mol. Genet. 2004, 13, 159–170. [CrossRef]
